Search results for "Opioid use disorder"
Telehealth visits may improve outcomes for opioid use disorder
A cross-sectional study of U.S. insurance claims found that buprenorphine initiation during a telehealth visit was associated with a 36% lower overdose rate than in person and that patients in the former group were more likely to refill their prescriptions.
https://acpinternist.org/weekly/archives/2023/09/12/1.htm
12 Sep 2023
Learn the latest on excessive alcohol use, opioid use disorder
This month's issue addresses alcohol use and misuse, prescribing buprenorphine, and improving health care's response to future pandemics.
https://acpinternist.org/archives/2023/03/learn-the-latest-on-excessive-alcohol-use-opioid-use-disorder.htm
1 Mar 2023
One-third of primary care physicians do not support medications for opioid use disorder
Fewer than a quarter of surveyed primary care physicians expressed interest in treating patients with opioid use disorder, and only 11.8% were interested in obtaining a waiver to prescribe buprenorphine.
https://acpinternist.org/weekly/archives/2020/04/21/2.htm
21 Apr 2020
Big barrier to buprenorphine removed
The U.S. government no longer requires an X waiver to treat patients with buprenorphine for opioid use disorder.
https://acpinternist.org/archives/2023/03/big-barrier-to-buprenorphine-removed.htm
1 Mar 2023
Daily medication appears more cost-effective than monthly injections for opioid use disorder
Over 24 weeks, extended-release naltrexone cost an average of $5,317 more than buprenorphine-naloxone, primarily because the former was more expensive and required a longer detoxification period.
https://acpinternist.org/weekly/archives/2018/12/18/1.htm
18 Dec 2018
Q&A: DEA requires addiction training for all prescribers
The Drug Enforcement Administration is requiring eight hours of training related to substance use disorder treatment, sending clinicians scurrying to their continuing education providers for help.
https://acpinternist.org/archives/2023/05/dea-requires-addiction-training-for-all-prescribers.htm
1 May 2023
Pandemic may have led to changes in buprenorphine treatment initiation, retention
While more U.S. patients received buprenorphine for opioid use disorder between March 13 and Dec. 1, 2020, than during the same period in 2019, there were about 17% fewer new prescriptions than expected, a recent study found.
https://acpinternist.org/weekly/archives/2022/12/13/2.htm
13 Dec 2022
Leadership, Leadership Day, and ‘purple’ as a guide
ACP's Chief Advocacy Officer issues a challenge to members of the College to be more “purple” in their outlook in order to achieve goals as a team, even when they disagree.
https://acpinternist.org/archives/2023/07/leadership-leadership-day-and-purple-as-a-guide.htm
1 Jul 2023
New blood donor recs; menopause drug approved
This column reviews recent recalls, alerts, and approvals.
https://acpinternist.org/archives/2023/07/new-blood-donor-recs-menopause-drug-approved.htm
1 Jul 2023
Few internal medicine residency programs provide clinical opioid-related training
A 2019 survey of members of the Association of Program Directors in Internal Medicine found that while 82% of programs required some training in safe opioid prescribing and opioid use disorder treatment, few programs required clinical experiences.
https://acpinternist.org/weekly/archives/2021/11/09/5.htm
9 Nov 2021